Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Current Deferred Revenue (2020 - 2022)

GeneDx Holdings (WGS) has disclosed Current Deferred Revenue for 3 consecutive years, with $40000.0 as the latest value for Q4 2022.

  • On a quarterly basis, Current Deferred Revenue fell 91.54% to $40000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $40000.0, a 91.54% decrease, with the full-year FY2022 number at $40000.0, down 91.54% from a year prior.
  • Current Deferred Revenue was $40000.0 for Q4 2022 at GeneDx Holdings, down from $3.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $3.8 million in Q1 2022 to a low of $40000.0 in Q4 2022.
  • A 3-year average of $2.0 million and a median of $2.1 million in 2021 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 136.69% in 2022; the steepest drop was 91.54% in 2022.
  • GeneDx Holdings' Current Deferred Revenue stood at $3.8 million in 2020, then plummeted by 87.59% to $473000.0 in 2021, then plummeted by 91.54% to $40000.0 in 2022.
  • Per Business Quant, the three most recent readings for WGS's Current Deferred Revenue are $40000.0 (Q4 2022), $3.2 million (Q2 2022), and $3.8 million (Q1 2022).